Collaborating Entity
Kalam Institute of Health Technology: A JBI Affiliated Group
Name
Dr. Kavita Kachroo
eMail
kavita.k@kiht.in
Question

What is the Clinical Effectiveness of orphan drugs  in Covid-19 patients when compared with Standard Care?

Population

Covid-19 Patients
According to World Heath Organisation on 16th August 2021, there have beern 207,173,086 confirmed cases of Covid-19, including 4,361,996 deaths, reported to WHO. Where as in India 16th August 2021, there have been 32,225,513 confirmed cases of Covid-19 with 431,642 deaths,reported to WHO.

Intervention
Intervention (quantitative - effectiveness)
Intervention Description

Orphan Drugs
An Orphan Drug is a Pharmaceutical agent that is used to treat a rare medical condition. Orphan Drugs which are used in Covid-19 like Anakinra, Bevacizumab, Sargramostim, Nitazoxanide, Barcitinib.

Comparator
Comparator (quantitative - effectiveness)
Comparator Description

Standard Treatment
The standard treatment like (Paracetamol, Naproxen, Ivermectin, hydroxychloroquine, steroids, budisonide, Anti-tussive, Anticoagulant, Anti-inflammatory /immunomodulatory therapy) fails in decreasing the viral load.

Outcome
Outcome & Context (comprehensive)
Outcome Description

Primary Outcome: Mortality
Secondary Outcome: Orphan Drugs (Clinical Effectiveness)

regtitle datecreated
Wed, 08/25/2021 - 09:50
regtitle dateupdated
Wed, 08/25/2021 - 09:50